Vimarsana
Biggest News Aggregation in the World

Page 2 - Dror Harats News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dror Harats. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dror Harats Today - Breaking & Trending Today

Aleph Farms Increases Production Capabilities with VBL Therapeutics Facility Acquisition and ESCO Aster Partnership - Vimarsana News

Aleph Farms Increases Production Capabilities with VBL Therapeutics Facility Acquisition and ESCO Aster Partnership

Efficient capital deployment in Israel and Singapore designed to support scale-up in key markets Aleph Farms, the first company to grow cultivated steaks directly from non-modified cow cells, today

Aleph Farms Increases Production Capabilities with VBL Therapeutics Facility Acquisition and ESCO As - Vimarsana News

Aleph Farms Increases Production Capabilities with VBL Therapeutics Facility Acquisition and ESCO As

Efficient capital deployment in Israel and Singapore designed to support scale-up in key marketsREHOVOT, Israel--(BUSINESS WIRE)--#COP26--Aleph Farms, the first company to grow cultivated steaks directly from non-modified cow cells, today announced that it has acquired a manufacturing facility in Modi’in, Israel, an...

VBL Therapeutics tanks after clinical trial failure - Vimarsana News

VBL Therapeutics tanks after clinical trial failure

The trial of VBL's ofra-vec treatment for ovarian cancer did not meet any of its primary endpoints.

VBL Therapeutics to Participate in the Jefferies Healthcare Conference - Vimarsana News

VBL Therapeutics to Participate in the Jefferies Healthcare Conference

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
VBL Therapeutics Announces Appointment of Matthew Trudeau - Vimarsana News

VBL Therapeutics Announces Appointment of Matthew Trudeau

CCO appointment positions VBL to advance and accelerate commercialization strategy for ofra-vec (VB-111) Enrollment in the OVAL Study, a 400 patient...